Clinical trialNCT00023452CompletedPhase 3Interventional

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

SponsorCenters for Disease Control and PreventionEnrollment8,053Tuberculosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elsa M Villarino, MD, MPH
Centers for Disease Control and Prevention
Study Director
clinicaltrials.gov ↗
Timothy Sterling, MD
Vanderbilt University Medical Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Universidade Federal Do Rio de Janeiro
Rio de Janeiro, Brazil

Canada

University of British Columbia
Vancouver, British Columbia, Canada
University of Manitoba
Winnipeg, Manitoba, Canada
Montreal Chest Institute Mcgill University
Montreal, Quebec, Canada

Spain

Agencia de Salut Publica
Barcelona, Spain

United States

Central Arkansas Veterans Health System
Little Rock, Arkansas, United States
la County/usc Medical Center
Los Angeles, California, United States
Ucsd Medical Center
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Denver Department of Public Health and Hospitals
Denver, Colorado, United States
Washington, D.C. Vamc
Washington D.C., District of Columbia, United States
Emory University, Department of Medicine
Atlanta, Georgia, United States
Chicago Va Medical Center (lakeside)
Chicago, Illinois, United States
Hines Va Medical Center
Hines, Illinois, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
New Jersey Medical School
Newark, New Jersey, United States
Columbia University/presbyterian Medical Center
New York, New York, United States
Harlem Hospital Center
New York, New York, United States
Carolinas Medical Center
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
University of North Texas Health Science Center
Fort Worth, Texas, United States
Michael Debakey Veterans Affairs Medical Center
Houston, Texas, United States
Audi L. Murphy Va Hospital
San Antonio, Texas, United States
Seattle King County Health Department
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Isoniazid daily for 9 monthsRPT + INH once weekly for 3 months given by DOT

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2001
Primary completion: 31 Oct 2010
Completion: 30 Sept 2013
Last update posted: 27 Aug 2024
Registered enrollment: 8,053
Registry id: NCT00023452

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.